Aytu Bioscience Inc., of Englewood. Colo., said Armistice Capital has invested $5 million in the company in the form of a three-year senior secured note. The investment was made in conjunction with the company's licensing of Tuzistra XR (codeine polistirex/chlorpheniramine polistirex) and a complementary antitussive pending FDA approval and is intended to further support the growth of the company's commercial portfolio.